Almost 80% of individuals with chronic kidney disease (CKD) reside in low- and middle-income countries (LMICs) and are potentially underrepresented in randomized controlled clinical trials (RCTs). We assessed the global distribution of RCTs comparing pharmacological treatments for CKD over the past 2 decades, as well as the magnitude and evolution of participation by LMICs.

中文翻译：

---

CKD 药物试验中低收入和中等收入国家的代表：系统评价


近 80% 的慢性肾病 (CKD) 患者居住在低收入和中等收入国家 (LMIC)，并且在随机对照临床试验 (RCT) 中可能代表性不足。我们评估了过去 20 年来比较 CKD 药物治疗的随机对照试验的全球分布，以及中低收入国家参与的规模和演变。